IMMUNIC, INC. — Director's Dealing 2021

Mar 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2021-03-02

Reporting Person: Muehler Andreas (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-02	Common Stock	P	10006	$15.54	Acquired	294486	Direct

Footnotes

F1: Reflects the weighted average price of 10,006 shares of common stock of Immunic, Inc. purchased by the Reporting Person in multiple transactions on March 2, 2021 with sale prices ranging from $14.44 to $15.72 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F2: Consists of 10,006 shares of common stock held directly by the Reporting Person, and 284,480 shares of common stock held indirectly by Xanomed GmbH, an entity controlled by the Reporting Person.